Introduction {#s0005}
============

During the development of multicellular organisms, a recurrent mechanism for tissue patterning is the formation of morphogen gradients. The original definition of a morphogen is a molecule produced at a localised source which then diffuses into the surrounding tissue to provide positional information and specify different cell fates in a dose-dependent manner ([@bib73]). Bone morphogenetic proteins (BMPs) have been described as morphogens and BMP gradients have been documented in various developing organisms such as the sea urchin, *Drosophila*, *Xenopus*, zebrafish, and mouse ([@bib58]). The best understood models of BMP gradient formation are the *Drosophila* BMP activity gradients. In the *Drosophila* embryo, the BMP gradient that is required for the specification of dorsal and lateral tissues involves the redistribution of the BMP ligands within a uniform expression domain ([@bib52]). In the developing *Drosophila* wing, a BMP gradient forms across the Anterior/Posterior (A/P) axis which extends beyond the source of the BMP ligand Decapentaplegic (Dpp; BMP4 orthologue). It is still debated whether this involves free diffusion, restricted diffusion, and/or transcytosis of Dpp ([@bib13; @bib29; @bib63; @bib77]). Much less is understood about how BMP gradients are formed in vertebrate embryos. There is increasing evidence that the establishment of these gradients is highly complex and finely regulated ([@bib73]), and that mechanisms operating in *Drosophila* are not sufficient to explain them. A prerequisite for studying gradients in early vertebrate embryos is a sensitive molecular tool for directly visualising them.

The BMPs, along with the related growth and differentiation factors (GDFs), constitute a subfamily of the transforming growth factor β (TGF-β) superfamily ([@bib61]). BMPs and GDFs signal through heteromeric serine/threonine kinase receptor complexes comprising type II and type I receptors (also called ALKs). Ligand binding promotes phosphorylation and activation of the type I receptor by the type II receptor, leading to phosphorylation of a subset of receptor-activated Smads (R-Smads) ([@bib46]). Once activated, the R-Smads form heteromeric complexes with Smad4, which accumulate in the nucleus and regulate target gene transcription. Importantly, the Smads constantly shuttle between the cytoplasm and the nucleus in both the presence and absence of signalling and the levels of activated complexes in the nucleus are determined by the relative activities of the receptor kinases in the cytoplasm and a nuclear phosphatase. In the presence of signal the Smad nucleocytoplasmic shuttling provides a sensing mechanism for receptor activity ([@bib61]). For many years, TGF-β superfamily signalling was divided into two distinct branches with respect to the R-Smads: BMPs and GDFs were thought to signal exclusively through Smad1, Smad5 and Smad8, whilst TGF-β, Activin and Nodals signalled through Smad2 and Smad3 ([@bib61]). However, it is now established that in most cell types TGF-β additionally robustly activates Smad1 and Smad5 ([@bib5; @bib10; @bib19; @bib41; @bib75]). Hence, monitoring the phosphorylation status of a particular R-Smad is not a reliable way to discriminate signalling by different ligands. A more specific method is to exploit reporter plasmids with binding sites for transcription factors specifically activated by the pathway in question. For BMP/GDF pathways, such a reporter was generated in which BMP responsive elements (BREs) from the mouse *Id1* enhancer, which bind phosphorylated Smad1/5--Smad4 complexes, drive *luciferase* expression ([@bib34]). Most importantly, this BRE-*luciferase* reporter exclusively responds to BMP/GDF signals and not to TGF-β signals, despite the latter\'s ability to phosphorylate and activate Smad1/5 ([@bib10; @bib21; @bib41]). We have recently generated a fluorescent reporter transgenic zebrafish line using a modified version of this BRE-*luciferase* reporter (BRE-*mRFP*) ([@bib76]).

In zebrafish embryos, a BMP activity gradient that is stronger ventrally during the blastula and gastrula stages is required to pattern the embryo along its dorsal/ventral (D/V) axis. The existence of a BMP activity gradient is evident when monitoring the expression of BMP target genes during gastrulation, such as the *bmp* ligands themselves or the ventral ectoderm markers *gata2* and *ΔNP63* ([@bib2; @bib49]). The first direct visualisation of the zebrafish BMP activity gradient was obtained using anti-phosphorylated Smad1/5 (p-Smad1/5) immunostaining ([@bib70]). This study concluded that a ventral to dorsal gradient of nuclear p-Smad1/5 is set up between 4.75 h and 5 h post-fertilisation (hpf; 30--40% epiboly stages). However, it is not known if the newly established BMP activity gradient (as detected with p-Smad1/5) is also reflected in transcriptional output as early as 30--40% epiboly, nor how it is formed.

Here we exploit our BRE-*mRFP* transgenic reporter line to determine the mechanism by which the ventral to dorsal BMP activity gradient is established. We first definitively prove that mRFP expression faithfully reports BMP and GDF signalling at both early and late stages of development. Then, taking advantage of the unstable nature of *mRFP* mRNA and the sensitivity of its detection, we readily visualise the ventral to dorsal BMP transcriptional activity gradient that is generated during blastula stages, showing it is established by the 40% epiboly stage. We demonstrate using single and double in situ hybridisation (ISH) that the graded BMP transcriptional activity occurs in a pre-established domain of graded *bmp* ligand transcripts. Using anti-BMP2B antibody staining, we also show that graded *bmp* ligand transcription results in graded protein expression. Moreover, in contrast to the mechanisms of BMP gradient formation in *Drosophila*, our results provide no evidence for diffusion or re-distribution of the BMP ligands during BMP gradient formation. Finally, we define the sequence of signalling events that lead to graded *bmp* transcription to generate a robust BMP activity gradient.

Materials and methods {#s0010}
=====================

Fish maintenance, screening, strains and crosses {#s0015}
------------------------------------------------

The zebrafish colony was maintained as described ([@bib72]). Founders for the BRE-*mRFP* transgene (20% of F0 screened, *n*=49) were identified by crossing injected adult zebrafish to wild-type and screening their progeny for mRFP fluorescence at 24 hpf. Experiments described here used F2, F3, or F4 progeny of five different founders. The *swr* ^TA72A^ allele is a strong loss-of-function allele corresponding to an ENU-induced point mutation in the zebrafish *bmp2b* termination codon ([@bib31]).

Plasmids, mRNAs, morpholinos and injections {#s0020}
-------------------------------------------

The *mRFP* ORF was amplified from pcDNA-*mRFP*-N and cloned into pGL3-BRE-*luciferase* ([@bib34]). BRE-*mRFP* was then amplified from pGL3-BRE-*mRFP* and cloned into pT2KXIGΔin. To generate the BRE-*mRFP* transgenic line the pT2KXIGΔin-BRE-*mRFP* plasmid DNA (20 ng/μl) was co-injected with *transposase* mRNA (25 ng/μl) as described ([@bib28; @bib71]). The *noggin1* and *chordin* ORFs were amplified from mid-gastrulation stage cDNA and cloned into pGEM-T and pCS2+, respectively. The following mRNAs were injected: CA-*alk8* (7.5 ng/μl) ([@bib3]), *bmp2b* (50 ng/μl) ([@bib76]), *chordin* (320 ng/μl), *membrane mRFP* (50 ng/μl) ([@bib30]) and *cherry H2B* (80 ng/μl) ([@bib74]). The following MOs (Genetools, LLC) were used: *dharma* ([@bib65]), *chordin* ([@bib48]), *gdf6a* ([@bib16]), *bmp2b* ([@bib23]) and *bmp4* ([@bib7]). All MOs were injected at 6 ng/nl except the *gdf6A* and *bmp2b* MOs which were at 3 ng/nl. A volume of approximately 2.5 nl of DNA, mRNA and/or MO was injected per embryo.

In situ hybridisation, immunofluorescence, and movies {#s0025}
-----------------------------------------------------

The following antisense probes were used: *mRFP* ([@bib76]), *dharma* ([@bib32]), *noggin1*, *chordin* ([@bib43]), *goosecoid* ([@bib67]), *bmp2b* ([@bib31]), *bmp4* ([@bib57]), and *bmp7a* ([@bib60]). The standard ISH protocol was essentially as described ([@bib26]) with the addition of 5% dextran sulphate to the hybridisation buffer ([@bib36]). The double fluorescent ISH (DFISH) using DIG- and DNP-labelled probes and revealed with fluorescein tyramide and Fast Blue substrates was modified from [@bib37] (detailed protocol available upon request). For p-Smad1/5 (Cell Signalling 9511, 1:100) immunofluorescence (IF), the protocol was as described ([@bib70]). The BMP2B (Tebu-Bio 55707, 1:500) and pMAPK (Sigma M8159, 1:500) IF protocols required an antigen retrieval step ([@bib24]). For ISH combined with IF, ISH was performed first. After ISH substrate development (Cy5 tyramide), embryos were washed in 1X PBS to stop the colourimetric reaction, then immersed in IF blocking solution before proceeding with IF. Embryos that had undergone colourimetric ISH were equilibrated in 80% glycerol and photographed using a Leica DFC420C camera mounted on a Leica MZ-FLIII dissecting microscope. DFISH, immunostained and/or BRE-*mRFP* samples were counterstained with DAPI (Roche 10 236 276 001), Hoechst 33342 (Invitrogen H1399), or DRAQ5 (Biostatus DR50200), mounted in 0.8% low melt agarose (Sigma-Aldrich A9045) in glass-bottom microwell dishes (MatTek P35G-1.5--14-C) and imaged using a Zeiss LSM710 inverted confocal microscope. Movies were acquired using a Zeiss LSM710 inverted or a Zeiss LSM700 upright confocal microscope and live embryos were mounted in low-melt agarose in fish water supplemented with anaesthetic. Supplementary movie 4 was obtained using a Nikon ECLIPSE TE2000-E inverted wide field microscope and an Andor iXon^EM^+ DU-888 back-illuminated EMCCD scientific camera. Images and movies were acquired and/or processed with the following software packages: Leica Application Suite, Zeiss Zen, Zeiss LSM Image Browser, Metamorph, Image J and Adobe Photoshop.

Protein preparation and Western blotting {#s0030}
----------------------------------------

Embryonic protein extracts were prepared as described ([@bib76]). The following antibodies were used: rabbit anti-mRFP (Invitrogen R10367) (Fig. S3), mouse anti-mRFP (SignalChem R46-61M-100) (Fig. S2), rabbit anti-pSmad2 (a mixture of Millipore AB3849 and 04953), mouse anti-pMAPK (Sigma M8159), mouse anti-Actin (Sigma 3853) and goat anti-MCM6 (Santa Cruz sc-9843).

Chemical inhibitor treatments {#s0035}
-----------------------------

LDN-193189 (gift from Paul Yu), SU5402 (Calbiochem 572631), and SB-505124 (Tocris Bioscience 3263) stocks were made in DMSO. These inhibitors were diluted in fish water to obtain the desired final concentration. 8- to 16-cell stage embryos were immersed in fish water supplemented with either DMSO (control) or the chemical inhibitors.

Results {#s0040}
=======

Characterisation of mRFP expression in BRE-*mRFP* embryos {#s0045}
---------------------------------------------------------

To study BMP transcriptional activity and gradient formation during zebrafish development, we used our previously generated BRE-*mRFP* reporter transgenic line ([@bib76]), employing both ISH for *mRFP* and direct observation of mRFP fluorescence in this line to assess BMP/GDF activity.

To observe early BMP signalling, we visualised *mRFP* mRNA, which gives a very sensitive and dynamic readout. *mRFP* RNA is expressed ubiquitously in 8-cell stage embryos ( [Fig. 1](#f0005){ref-type="fig"}A), suggesting that some *mRFP* mRNA is maternally deposited. *mRFP* mRNA is also ubiquitous during blastula stages before and after the onset of zygotic transcription, at the 512-cell and sphere stages, respectively ([Fig. 1](#f0005){ref-type="fig"}B). During gastrulation, *mRFP* transcripts are strongly reduced dorsally and are enriched ventrally in both the mesoderm and ectoderm, and thus transgenic embryos display a clear ventral to dorsal BMP activity gradient ([Fig. 1](#f0005){ref-type="fig"}C). During somitogenesis, *mRFP* expression is highly dynamic ([Fig. 1](#f0005){ref-type="fig"}D, S1). Most notably, *mRFP* mRNA is detected in the newly formed somites, the developing eyes, tailbud and presomitic mesoderm, consistent with studies implicating BMP activity in these tissues ([@bib14; @bib16; @bib53; @bib54]). Finally, at 28 hpf, *mRFP* mRNA is found in additional tissues such as the pineal gland, the developing heart, and the pectoral fin buds ([Fig. 1](#f0005){ref-type="fig"}E).

In BRE-*mRFP* embryos, mRFP fluorescence is only first visible around the 6-somite stage, when a strong signal is seen in the tail bud and presomitic mesoderm (Fig. S2A). This delay in detection is due to insufficient mRFP protein being synthesised during gastrulation for direct mRFP fluorescence visualisation, as full-length mRFP protein is virtually undetectable before the 6-somite stage using Western blotting (Fig. S2B). During somitogenesis, the strongest mRFP protein expression domains are the tail bud and the presomitic mesoderm (Fig. S2A; [Videos S1,S2](#ec0005 ec0010){ref-type="fig"}), thereby confirming the in situ results. Most notably, at 24 hpf, strong mRFP fluorescence is detected in the dorsal retina, the epiphysis/pineal gland, the epidermis, the cloaca, and the somites (Fig S2A and [Video S3](#ec0015){ref-type="fig"}) ([@bib1; @bib8; @bib16; @bib38; @bib53; @bib54; @bib59]). In addition, mRFP fluorescence is found in the cells of the midbrain--hindbrain border and the trigeminal ganglia (Fig. S2A) (data not shown). Finally, mRFP fluorescence is detected in the atrioventricular canal of 50 hpf transgenic embryos ( [Video S4](#ec0020){ref-type="fig"}), consistent with reported BMP activity during mammalian early heart valve formation in the BRE-*GFP* transgenic mouse ([@bib45]).

The BRE-*mRFP* transgenic zebrafish is a bona fide in vivo reporter for BMP/GDF activity. {#s0050}
-----------------------------------------------------------------------------------------

To establish unequivocally that mRFP expression reflects BMP/GDF signalling, we manipulated BMP signalling at different times during embryogenesis and assessed its effect on mRFP mRNA or protein levels.

Stimulation of BMP signalling using overexpression of BMP2B (a zygotic BMP ligand) ([@bib49]) and the constitutively-active BMP receptor CA-ALK8 ([@bib3]) or knockdown of the BMP inhibitor Chordin ([@bib62]) resulted in increased *mRFP* expression and expansion of the *mRFP* domain to the dorsal side ( [Fig. 2](#f0010){ref-type="fig"}A). Conversely, overexpression of Chordin and the BMP antagonist Noggin ([@bib79]) completely abolished *mRFP* expression at 70--80% epiboly ([Fig. 2](#f0010){ref-type="fig"}A) ([@bib76]). Thus, changes in BMP activity are reflected in *mRFP* expression along the D/V axis of the gastrulating embryo.

We also used a genetic approach to inhibit zygotic BMP activity, investigating *mRFP* expression in a *bmp2b*-deficient background ([Fig. 2](#f0010){ref-type="fig"}B). At 70% epiboly, *mRFP* expression is strongly reduced in homozygous *swr* ^TA72A^ (*bmp2b* ^−^) embryos. From bud stage/early somitogenesis, *swr* ^TA72A^/*swr* ^TA72A^ embryos display a striking elongated morphology ([@bib47]) unlike their *swr* ^TA72A^/+ and wild-type siblings. In 4-somite stage *swr* ^TA72A^ homozygous embryos, *mRFP* expression is also strongly reduced. No difference in *mRFP* expression between wild-type and *swr* ^TA72A^ heterozygous siblings was detected (data not shown).

BMP activity is important at the end of gastrulation to specify ventro-posterior fates, including formation of the cloaca, the common opening of the urogenital and digestive tracts in zebrafish ([@bib54; @bib55]). BMP4 is thought to be the critical zygotic ligand for the specification of cloacal fates as severe *bmp4* ^ST72^ homozygous zebrafish mutants do not form a proper cloaca ([@bib68]). Injection of a splice-blocking MO that targets *bmp4* mRNA ([@bib7]) results in severely reduced *mRFP* expression in the cloaca of 28 hpf embryos, but strikingly, has no effect on *mRFP* expression in the somites where other BMP ligands must contribute to *mRFP* transcription ([Fig. 2](#f0010){ref-type="fig"}C).

The dorsal retina is another region of high mRFP expression ([Fig. 1](#f0005){ref-type="fig"}E, S1, S2A). The GDF6A ligand is required for p-Smad1/5 activation in the dorsal retina ([@bib16]), suggesting that it might be the ligand responsible for mRFP expression in this tissue. Injection of a *gdf6a* splice-blocking MO results in reduced dorsal retina *mRFP* mRNA expression as well as reduced mRFP fluorescence in 26 hpf embryos ([Fig. 2](#f0010){ref-type="fig"}D), confirming that the BRE-*mRFP* transgenic line is also sensitive to changes in signalling by ligands from the GDF subfamily. We were unable to detect any effect of GDF6A knockdown on *mRFP* expression in other tissues such as the somites, despite a recent study implicating GDF6A as a factor required for somitic BMP activity during myogenesis ([@bib50]).

Finally, we decreased BMP/GDF signalling globally in fish embryos using the chemical inhibitors Dorsomorphin and LDN-193189, which target the type I BMP/GDF receptors, and lead to a dorsalized phenotype ([@bib6; @bib78]) (Fig. S3). The chemical inhibitors are autofluorescent, resulting in considerable background when mRFP fluorescence is visualised. However, inhibition of mRFP expression is readily detected by *mRFP* ISH and Western blotting for mRFP protein (Fig. S3).

Taking all the results in this section together, we conclude that mRFP expression in the BRE-*mRFP* transgenic embryos is an accurate readout of dynamic BMP/GDF activity at all stages of development examined.

The initial ventral to dorsal BMP transcriptional activity gradient is established between 30% and 40% epiboly {#s0055}
--------------------------------------------------------------------------------------------------------------

The ability to visualise the ventral to dorsal BMP activity gradient in the BRE-*mRFP* embryos by monitoring levels of *mRFP* mRNA gave us a unique opportunity to investigate in detail how this gradient forms.

From the 8-cell to the 30% epiboly stage, *mRFP* expression is uniform ( [Fig. 3](#f0015){ref-type="fig"}). The *mRFP* transcripts detected at the 8-, 256-, and 512-cell stage must be deposited maternally. In contrast, specific nuclear p-Smad1/5 staining is only apparent from the 512-cell stage onwards ([Fig. 3](#f0015){ref-type="fig"}) and must occur as a result of maternal BMP signalling initially ([@bib20; @bib66]), then as a result of zygotic BMP signalling. At 40% epiboly, *mRFP* mRNA is clearly enriched ventrally and expressed in a graded fashion in BRE-*mRFP* embryos ([Fig. 3](#f0015){ref-type="fig"}). Comparison of the p-Smad1/5 staining with the *mRFP* expression pattern revealed that decrease of p-Smad1/5 from the dorsal side at 30% epiboly fractionally preceded loss of *mRFP* expression ([Fig. 3](#f0015){ref-type="fig"}). Hence, the BMP transcriptional activity gradient (*mRFP*) is established between 30% and 40% epiboly and occurs minutes after ventral enrichment of p-Smad1/5. Notably, clearance of *mRFP* transcripts dorsally occurs in a very short time frame (\~20 min), confirming that the *mRFP* mRNA half-life is very short. Thus, observing *mRFP* transcripts at these early stages provides a very dynamic readout of the BMP activity gradient. Moreover, this comparative experiment shows that in the case of early zebrafish embryogenesis, it is also possible to use p-Smad1/5 immunostaining as a readout for BMP pathway activation.

The BMP transcriptional activity gradient is established in a domain of graded ligand transcription {#s0060}
---------------------------------------------------------------------------------------------------

Having determined exactly when the BMP activity gradient is initially formed, we explored the mechanism underlying it. The expression of zygotic *bmp* ligands is thought to be set up in two key steps. First, after the mid-blastula transition (MBT; \~3.25 hpf), a combination of the maternal BMP ligand GDF6A (possibly acting through maternal ALK8 and Smad5) and the transcription factor POU2 induce the ubiquitous expression of zygotic *bmp2b* and *bmp7a*, which is shortly followed by *bmp4* expression ([@bib35]). Second, the sequential action of dorsally-expressed negative regulators contributes to the increase in ventral expression of the BMP ligands. As early as sphere stage (\~4 hpf), Dharma, a transcriptional repressor that is expressed in the dorsal-most blastomeres, directly represses *bmp2b* transcription ([@bib33; @bib39]). Subsequently, a combination of the dorsally-secreted BMP antagonists Noggin1 and Chordin acts to inhibit BMP signalling, with Chordin being essential for BMP signalling repression ([@bib9]). It is not clear though when Chordin begins to confer its effect on BMP ligand expression. In addition, there is evidence that the FGF signalling pathway acts on the dorsal side to repress *bmp* transcription ([@bib17]). As a result of all these interactions *bmp* ligand expression is clearly graded by the end of the blastula stage ([@bib17; @bib66]). However, it is not known how the expression domain of the ligands relates to the BMP activity gradient or to transcriptional output during these critical stages.

To establish the sequence of events between dome stage and 40% epiboly, we compared the timing and pattern of *mRFP* mRNA expression with that of the three zygotic BMP ligands: BMP2B and BMP7A, which act as obligate heterodimers ([@bib40]), and BMP4. We also investigated expression at the level of mRNA of the BMP antagonists expressed dorsally at blastula stages, Chordin and Noggin1, the transcriptional repressor Dharma, as well as dorsal FGF activity. At dome stage, *dharma*, *noggin1* and *chordin* are all expressed dorsally, and in the case of *noggin1* and *chordin,* expression increases at 30% and 40% epiboly ( [Fig. 4](#f0020){ref-type="fig"}A). We monitored FGF activity by immunostaining for di-phosphorylated MAPK (pMAPK) ([@bib27]), and demonstrated that FGF is active at all stages examined, with stronger activity detected on the dorsal side. This is especially clear for pMAPK staining at dome stage ([Fig. 4](#f0020){ref-type="fig"}A). *bmp2b* and *bmp7a* transcripts are expressed uniformly throughout most of the embryo at dome stage, except on the most dorsal side, where a clear gap in staining is visible ([Fig. 4](#f0020){ref-type="fig"}A). At 30% and 40% epiboly, *bmp2b* and *bmp7a* show a clear asymmetric pattern, being stronger on the ventral side and weaker on the dorsal side ([Fig. 4](#f0020){ref-type="fig"}A), in agreement with reports that *bmp2b* and *bmp7a* are expressed uniformly upon activation of zygotic transcription, then become enriched ventrally ([@bib22; @bib39]). *bmp4* expression, in contrast, is detected ubiquitously at dome stage ([Fig. 4](#f0020){ref-type="fig"}A) and only becomes ventrally enriched later at 30% and 40% epiboly ([Fig. 4](#f0020){ref-type="fig"}A) ([@bib35]). Importantly, despite *bmp* ligands being expressed in a graded manner from 30% epiboly, *mRFP* transcripts remain uniform in the majority of embryos examined. In contrast, at 40% epiboly, the gradient of *mRFP*, reflecting BMP transcriptional activity, was evident, and strikingly, it appears very similar to the expression patterns of the ligands ([Fig. 4](#f0020){ref-type="fig"}A).

To confirm that the gradient of BMP ligand expression was the same as the gradient of BMP activity, we used DFISH for *bmp2b* and *mRFP* ([Fig. 4](#f0020){ref-type="fig"}B). As DFISH caused substantial autofluorescence from the yolk we visualised *mRFP* and *bmp2b* mRNAs at the blastoderm margin only. As expected, *bmp2b* is expressed in a ventral to dorsal gradient at both 30% and 40% epiboly and consistent with the single ISH results ([Figs 3](#f0015){ref-type="fig"} and [4](#f0020){ref-type="fig"}A), *mRFP* is only expressed in a gradient from 40% epiboly. DFISH shows a very good overlap of *bmp2b* and *mRFP* transcripts at 40% epiboly, confirming that at this stage the BMP transcriptional activity gradient occurs in a pre-established domain of graded ligand transcription.

Graded *bmp* transcription results in a BMP protein gradient with little or no transcriptional activity at a distance from BMP protein-expressing cells {#s0065}
-------------------------------------------------------------------------------------------------------------------------------------------------------

Our observations that the transcripts of the three major BMP ligands are expressed in a gradient as early as 30% epiboly does not necessarily mean that the BMP proteins are also expressed in a gradient at that time. Indeed, post-transcriptional processing, diffusion, transport and other regulatory mechanisms could result in BMP protein expression differing from that of the *bmp* transcripts. As no data are available for endogenous BMP protein expression during early stages of zebrafish development, we used a new commercial zebrafish specific BMP2B antibody to visualise BMP2B protein expression.

Analysis of BMP2B protein expression revealed a graded staining pattern at all stages examined, from 30% to 75% epiboly ( [Fig. 5](#f0025){ref-type="fig"}A and data not shown). At 30% epiboly, strong BMP2B protein expression is detected on one side of the embryo, while BMP2B protein levels are much lower on the opposite side. At 60--70% epiboly, a clear gradient of BMP2B protein expression is detected in both the mesoderm and ectoderm. To confirm that the enrichment of BMP2B protein is indeed ventral, we compared BMP2B with pMAPK expression and found that strong BMP2B and pMAPK staining was obtained on opposite sides of the embryo at 30% epiboly (Fig. S4A). Using combined ISH for the dorsal marker *chordin* and IF for BMP2B, it was also evident that BMP2B proteins are enriched ventrally and expressed in a gradient during gastrulation (Fig. S4B). Close analysis of wild-type embryos injected with *membrane mRFP* mRNA revealed that the BMP2B protein is expressed in punctate cytoplasmic structures (Fig. S4C). Since the antibody used was raised against the prodomain region of zebrafish BMP2B (Tebu-Bio/Anaspec, personal communication), it is expected to detect pre-processed BMP2B. As a further check for specificity we performed IF in embryos overexpressing BMP2B and the nuclear marker Cherry H2B in a mosaic fashion and found that increased BMP2B immunoreactivity correlates with cells overexpressing BMP2B/Cherry H2B (Fig. S4D). We also injected embryos with a translation blocking *bmp2b* MO ([@bib23]) and examined BMP2B expression in the blastoderm at the 30% epiboly stage. BMP2B expression was reduced in the majority of the *bmp2b* morphants compared with controls ([Fig. 5](#f0025){ref-type="fig"}B).

We have shown at 40% epiboly that the gradient of *bmp2b* mRNA expression matches the BMP activity gradient read out by *mRFP* mRNA ([Fig. 4](#f0020){ref-type="fig"}B). In contrast to what has been reported for Dpp in the *Drosophila* wing ([@bib12; @bib18; @bib69]), this result strongly suggests that active BMP ligands do not diffuse significantly beyond the cells that synthesise them in the zebrafish embryo. Our ability to detect both an endogenous BMP protein and BMP transcriptional activity in the same embryo allowed us to determine whether transcriptional activity can be detected at a distance from BMP protein expressing cells. Using combined ISH for *mRFP* with IF for BMP2B in 40% and 70% epiboly BRE-*mRFP* embryos, we found that the expression of *mRFP* mRNA and BMP2B protein strongly overlap ([Fig. 5](#f0025){ref-type="fig"}C). Our antibody detects pre-processed BMP2B, and in principle, processed mature BMP2B, which we cannot detect, may diffuse further than the BMP2B-expressing cells. However, the fact that we do not detect any BMP transcriptional activity (*mRFP*) beyond cells expressing BMP2B suggests that processed BMP2B is not significantly diffusible.

For the first time therefore, we have shown the protein expression pattern of an endogenous BMP ligand in zebrafish. BMP2B protein is expressed in a ventral to dorsal gradient in the early zebrafish embryo, which recapitulates both the *bmp2b* mRNA expression, and the activity gradient read out by the mRFP reporter. Thus, taken together, our results provide no evidence that extensive diffusion of BMP2B protein occurs to generate the BMP transcriptional activity gradient detected with *mRFP.*

Graded *bmp* ligand transcription, established by dharma and FGF signalling and maintained through auto-regulation, determines the BMP activity gradient {#s0070}
--------------------------------------------------------------------------------------------------------------------------------------------------------

Since we have shown that graded *bmp* transcription precedes the formation of the BMP activity gradient, we next investigated how graded *bmp* transcription is established. Transcription of the BMP ligands is known to be under autoregulation from about 60% epiboly ([@bib31; @bib49; @bib60]). However, this does not appear to occur during blastula stages ([@bib17]). To inhibit BMP signalling during blastula stages, we used LDN-193189 treatment from the 8--16 cell stage onwards (Fig. S3) ([@bib6]) and found that most embryos still retained graded *bmp2b* transcript expression at 30% epiboly ( [Fig. 6](#f0030){ref-type="fig"}A), despite a clear effect on overall transcript levels, probably due to reduced maternal BMP signalling. This result demonstrates that graded *bmp2b* transcription at 30% epiboly is not dependent on zygotic BMP activity. Consistent with this view, Chordin knockdown, which should lead to increased BMP signalling, did not result in expanded *bmp2b* expression at 30% epiboly ([Fig. 6](#f0030){ref-type="fig"}B) ([@bib17]).

Having ruled out positive feedback by autocrine BMP signalling as important for establishing graded *bmp2b* expression at 30% epiboly, we tested the involvement of Dharma and FGF signalling ([@bib17; @bib33; @bib39]). The lack of *bmp2b* and *bmp7a* transcripts dorsally at dome stage is a strong indication of localised transcriptional repression by Dharma ([Fig. 4](#f0020){ref-type="fig"}A), and this was confirmed by the observation that injection of a *dharma* MO resulted in expanded *bmp2b* transcription at 30% epiboly in the majority of embryos examined ([Fig. 6](#f0030){ref-type="fig"}B). Notably, we found that ectopic *bmp2b* is only detected at the margin, where Dharma is expressed ([Fig. 4](#f0020){ref-type="fig"}A), but not in the dorsal ectoderm (see white dotted lines in [Fig. 6](#f0030){ref-type="fig"}B). Consistent with dorsal *bmp2b* being detected upon Dharma knockdown, we found that *dharma* morphants display increased *mRFP* expression dorsally at the margin in 40% epiboly embryos ([Fig. 6](#f0030){ref-type="fig"}C). Expression of pMAPK at dome and 30% epiboly stages indicates active FGF signalling in a dorsal to ventral gradient, with stronger activity occurring at dome stage ([Fig. 4](#f0020){ref-type="fig"}A). Using the FGF receptor inhibitor SU5402 ([@bib44]), we demonstrated that FGF signalling inhibition results in expansion of the domain of *bmp2b* expression to the dorsal side at 30% epiboly ([Fig. 6](#f0030){ref-type="fig"}A) ([@bib17]). Interestingly, SU5402 treatment also results in reduced *chordin* expression at this stage (Fig. S5). Thus, Dharma and FGF signalling are the critical factors for establishing the graded *bmp* transcription that is present at 30% epiboly, rather than auto-regulation via BMP signalling.

Chronologically, it is generally assumed that activity gradients are established as a direct consequence of morphogen diffusion/transport and that therefore these gradients are formed *de novo*. However, our *mRFP* ISH results show that BMP activity in blastula stage embryos is initially ubiquitous, then graded ([Fig. 3](#f0015){ref-type="fig"}). Hence there must be a molecular mechanism that results in clearance of *mRFP* transcripts dorsally ([Fig. 6](#f0030){ref-type="fig"}D). Indeed, our data indicate that at 40% epiboly, when the gradient of BMP activity is established, it faithfully reflects the gradient of BMP ligand transcription ([Fig. 4](#f0020){ref-type="fig"}B). However, our *mRFP* ISHs and p-Smad1/5 staining indicates that BMP activity is initially ubiquitous and is cleared from the dorsal side between 30% and 40% epiboly ([Fig. 3](#f0015){ref-type="fig"}) ([@bib70]). This occurs after the *bmp* transcripts disappear dorsally, suggesting that this might occur at the level of BMP protein inhibition (residual dorsal BMP protein), if BMP receptors act to constantly monitor ligand levels. This inhibition of signalling is most likely mediated by Chordin. To test this idea we knocked down Chordin with a MO and investigated the effect on *mRFP* mRNA levels at 40% epiboly when they are normally graded. We could clearly demonstrate that in *chordin* morphants the BMP activity gradient was abolished and *mRFP* expression was uniform ([Fig. 6](#f0030){ref-type="fig"}C). This occurs despite the fact that auto-regulation of *bmp2b* transcription only occurs after that stage (Fig. S6). We therefore conclude that between 30% and 40% epiboly, expression of Chordin on the dorsal side of the embryo must contribute to a loss of dorsal BMP activity, and that after 40--50% epiboly the BMP activity gradient becomes maintained by the gradient of ligand transcription.

Discussion {#s0075}
==========

Using ISH for *mRFP* in our BRE-*mRFP* transgenic line, which is a highly sensitive reporter for BMP/GDF signalling, we can visualise the dynamics of BMP signalling in early zebrafish embryos. We have shown that the BMP transcriptional activity gradient is established by 40% epiboly and is preceded by graded expression of BMP ligands (mRNA and protein). For the first time, we are able to detect the expression of an endogenous BMP protein, BMP2B, and found that it is expressed in a gradient during blastula and gastrula stages and that no extensive diffusion of BMP2B occurs to generate transcriptional activity at a distance. Our analysis strongly supports the notion that the BMP activity gradient in zebrafish occurs as a result of graded BMP expression and does not fit the classical models of gradient formation, where ligands synthesised from a local source would diffuse away in order to produce a signalling gradient.

A powerful tool to visualise BMP/GDF activity {#s0080}
---------------------------------------------

We confirmed using various experimental approaches that mRFP expression in our BRE-*mRFP* transgenic fish is a faithful readout of BMP/GDF activity. We found that mRFP fluorescence is only detected from early somitogenesis stages, which is most likely due to insufficient amounts of mRFP protein being produced. A similar lack of fluorescence at early stages has been reported for other transgenic reporter lines such as the Wnt reporter line TOPdGFP ([@bib11]), the Hedgehog pathway reporter line Gli-d:mCherry ([@bib64]) and the other zebrafish BMP reporter lines ([@bib1; @bib8; @bib38]). However, *mRFP* ISH in our strong BRE-*mRFP* lines visualised with either colourimetric or fluorescent substrates provides an excellent method to detect highly dynamic BMP transcriptional activity.

Timing and mechanisms of BMP activity gradient formation during blastula stages {#s0085}
-------------------------------------------------------------------------------

We found that the ventral to dorsal BMP activity gradient, revealed with *mRFP* ISH, is set up by 40% epiboly during the blastula period. The appearance of this gradient is preceded by the establishment of graded expression of BMP ligands which occurs between dome stage and 30% epiboly, and graded pathway activation read out by p-Smad1/5 levels occurs fractionally before the appearance of the *mRFP* gradient.

Using our results, combined with those from other studies ([@bib17; @bib35; @bib42]), we propose a model for BMP activity gradient formation that features the temporal and spatial requirement for specific signalling events ( [Fig. 7](#f0035){ref-type="fig"}). First, immediately after MBT, *bmps* are induced ubiquitously in the embryo. In contrast, the various BMP antagonists are locally induced by maternal β-catenin2 on the future dorsal side of the embryo. At dome stage, Dharma acts dorsally to locally repress *bmp2b* transcription. This symmetry-breaking event is followed by the action of FGF signalling at around 30% epiboly, which appears to act in a dorsal to ventral graded fashion to inhibit *bmp* ligand transcription in a dose-dependent manner. It is not yet clear how FGF signalling achieves this. As a result, by 30% epiboly, all three *bmp* transcripts are expressed in a graded manner. However, at this stage, our experiments suggest that there must be some residual BMP protein present on the dorsal side and that the BMP protein gradient lags behind the *bmp* transcript gradient ([Fig. 6](#f0030){ref-type="fig"}D). One clear indication of residual dorsal BMP protein is that p-Smad1/5 is still detected dorsally at 30% epiboly, albeit at slightly lower levels, and that *mRFP* transcripts are also strongly detected there ([Fig. 3](#f0015){ref-type="fig"}). Between 30% and 40% epiboly, inhibition of residual BMP protein function dorsally, via Chordin, rapidly leads to reduction in p-Smad1/5 levels and the disappearance of *mRFP* transcripts. Coupled with fast *mRFP* mRNA turnover, this contributes to the detection of the BMP transcriptional activity gradient at 40% epiboly. Interestingly, the rapid clearance of *mRFP* transcripts dorsally and the fact that Chordin knockdown inhibits this, suggest that BMP receptors must be able to monitor ligand activity at the cell surface and thus respond to rapid changes in signalling. We hypothesise that from 40% to 50% epiboly onwards, the BMP activity gradient becomes proportional to the amount of BMP transcripts and proteins, the expression of which is maintained through auto-regulation, combined with pathway inhibition by dorsally-expressed Chordin ([Fig. 7](#f0035){ref-type="fig"}; Fig. S6). One important feature of this model is that there is a complex level of interaction between all the molecular players. One example is that Chordin expression in the blastula is partially under the control of FGF and Nodal signaling (Fig. S5) and that optimal repression of *bmp2b* expression by FGF signalling also appears to require Chordin function ([@bib42]).

The zebrafish ventral to dorsal BMP activity gradient: An alternative model for the formation of BMP gradients {#s0090}
--------------------------------------------------------------------------------------------------------------

BMPs have long been assumed to be morphogens in the classical sense; that is that they are expressed from a local source and diffuse in the extracellular space to generate an activity gradient that is proportional to the amount of extracellular proteins. Not only is the issue of BMP extracellular diffusion still questionable, but the ways in which the activity gradients are formed in various developmental systems also show that the BMP signalling activity does not necessarily correlate with the amount of signalling BMP proteins ([@bib73]).

Our understanding of how BMP gradients first form comes predominantly from studies in *Drosophila*, where two different mechanisms have been uncovered (reviewed by [@bib58]). To generate the Dpp activity gradient that determines A/P patterning of the *Drosophila* wing, the Dpp ligand is secreted from a central stripe of cells in the wing imaginal disc and acts at a distance to form a concentration gradient both anteriorly and posteriorly ([@bib29; @bib56]). In contrast, the D/V Dpp activity gradient that forms in the embryonic *Drosophila* blastoderm results from redistribution of ligand within a uniform *dpp* expression domain. This is achieved by binding and transport of Dpp and a related ligand Screw with the ligand antagonists Twisted Gastrulation and Short Gastrulation (*Drosophila* Chordin) ([@bib52]). An analogous ligand shuttling mechanism was proposed to be responsible for the D/V BMP activity gradient in *Xenopus*, and was preferred over an alternative inhibition-based mechanism where an inhibition gradient of diffusible inhibitors like Chordin is created over a uniform field of activators ([@bib4]). However, there is little evidence for this mechanism in the *Xenopus* embryo and this issue is very controversial ([@bib15]).

We have shown that the early D/V BMP activity gradient is formed in a very different manner in zebrafish. Our study demonstrates that the BMP activity gradient is actually created in a tissue where activity is initially ubiquitous. Therefore this particular gradient is not created *de novo*. We also found that the control of BMP ligand transcription is the crucial determinant for generating a BMP activity gradient that is robust and sustainable - rather than extensive diffusion or redistribution of BMP proteins. Indeed, consistent with published data on the diffusion of BMP4 in *Xenopus* ([@bib25]) and cell transplantation experiments in zebrafish ([@bib51]), we find no evidence that zebrafish BMP proteins diffuse to generate signalling activity at a distance. Our data highlights the fact that each BMP gradient is unique in the way it is established and maintained.
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![***mRFP*****mRNA expression in BRE-*****mRFP*****zebrafish embryos** ((**A**)**--**(**E**)) ISH for *mRFP* mRNA in BRE-*mRFP* embryos. In the rightmost panel of (**C**), double ISH with *mRFP* and the dorsal marker *goosecoid* (*gsc*). V, ventral; D, dorsal; vs, ventral somites; ds, dorsal somites; tb, tailbud; psm, presomitic mesoderm; pg, pineal gland; dr, dorsal retina; ht, heart tube; pf, pectoral fin bud; s, somites.](gr1){#f0005}

![**mRFP expression in BRE-*****mRFP*****embryos is a*****bona fide*****readout for BMP and GDF activities** (**A**) *mRFP* ISH in BRE-*mRFP* embryos injected with *chordin, bmp2b* or CA*-alk8* mRNAs or *chordin* MO. (**B**) BRE-*mRFP* expression in *swr*^TA72A^*/swr*^TA72A^ homozygous embryos compared with +/+ or *swr*^TA72A^/+ siblings. The embryos shown resulted from a cross between *swr*^TA72A^*/+* heterozygotes that contained the BRE-*mRFP* transgene. (**C**) *mRFP* ISH in BRE-*mRFP* embryos injected with a control or *bmp4* MO. Arrows point to the cloaca. (**D**) BRE-*mRFP* embryos were injected with a control or *gdf6a* MO and mRFP expression in the dorsal retina was analysed (fluorescence and ISH). pg, pineal gland; s, somites. In (**A**) and (**B**), lateral views are shown; V, ventral; D, dorsal; A, anterior; P, posterior. In all cases, stages are indicated and the number of embryos out of the total analysed that showed the presented staining pattern is given. For (**B**), this number represents the number of homozygous mutant embryos out of the total number of embryos analysed.](gr2){#f0010}

![Establishment of the BMP activity gradient in zebrafish embryos. p-Smad1/5 IF and *mRFP* ISH in early stages BRE-*mRFP* embryos. Stages and views are indicated. V, ventral; D, dorsal. Arrows indicate the extent of *mRFP* staining. Note that the DAPI staining at the 8-cell stage did not resolve to single nuclei as the cells are dividing very quickly.](gr3){#f0015}

![The establishment of the BMP activity gradient occurs in a pre-established gradient of BMP ligand expression. (**A**) BRE-*mRFP* or wild-type embryos stained for *mRFP*, *dharma*, *noggin1, chordin, bmp2b*, *bmp7a* or *bmp4* mRNA by ISH or immunostained for pMAPK. Arrows indicate the extent of the domain of staining for a particular mRNA. The number of embryos out of the total analysed that showed the presented staining pattern is given. (**B**) DFISH for *mRFP* and *bmp2b* in blastula stages BRE-*mRFP* embryos. The fluorescent substrates used were fluorescein tyramide (*mRFP*) and Fast Blue (*bmp2b*, pseudocoloured in red). The images are the projection of a 10--12 picture stack taken at the margin of the blastoderm to avoid fluorescence from the yolk. V, ventral; D, dorsal.](gr4){#f0020}

![Graded expression of endogenous BMP2B protein results in graded transcriptional activity. (**A**) IF for BMP2B in wild-type embryos. (**B**) IF for BMP2B in control and *bmp2b* morphants. (**C**) Combined IF for BMP2B and ISH for *mRFP* in BRE-*mRFP* embryos. Note that there is some background staining for BMP2B that is due to autofluorescence from the yolk. Stages and views are indicated. The fluorescent substrate used for *mRFP* in (**C**) was Cy5 tyramide (pseudocoloured in red). In (**A**) and (**C**, bottom row), the pictures are the projection of a 25--30 stack of images taken from the edge of the embryo until about half way. In (**B**) and (**C**, top row), only the blastoderm margin was imaged. The white dotted line in (**C**, bottom row) shows the outline of the embryo. V, ventral; D, dorsal.](gr5){#f0025}

![Regulation of graded *bmp* ligand transcription by Dharma, FGF and BMP signalling and consequences for the transcriptional activity of the BMP pathway. (**A**) *bmp2b* ISH in 30% epiboly wild-type embryos treated with DMSO, LDN-193189 (LDN) or SU5402. (**B**) *bmp2b* ISH in 30% epiboly wild-type embryos injected with either control, *dharma*, or *chordin* MOs. Ectopic *bmp2b* expression is detected at the margin upon Dharma knockdown but not in the dorsal ectoderm (white dotted lines). (**C**) *mRFP* ISH in BRE-*mRFP* embryos injected with either control, *dharma*, or *chordin* MOs. The fluorescent substrate used in (**C**) was Fast Blue (pseudocoloured in red). Note that the images are projection of a 10--12 picture stack taken at the margin of the blastoderm to avoid fluorescence from the yolk. (**D**) Graphical representation of the levels of *mRFP*, *chordin*, and *bmp2b* mRNAs, as well as BMP and p-Smad1/5 proteins across the D/V axis at 30% and 40% epiboly. Between these two stages, Chordin acts to antagonise residual BMP activity dorsally, resulting in a gradient of *mRFP* at 40% epiboly that reflects the gradient of BMP ligand transcription. For all panels in ((**A**)--(**C**)), stages and/or views are indicated. Arrows indicate the limit of the expression domain of the transcripts analysed. V, ventral; D, dorsal.](gr6){#f0030}

![Sequence of signalling events leading to graded BMP ligand transcription and hence a gradient of BMP activity. While the dorsal determinants are actively induced (simplified representation; cross-regulation is not shown), the transcription of zygotic BMPs is initially ubiquitous. The symmetry-breaking event for *bmp* expression is the transcriptional repression of *bmp2b* (and possibly *bmp7a*) by Dharma. FGF signalling is critical for establishing graded *bmp* expression. Both graded *bmp* ligand expression and the BMP activity gradient are subsequently mostly maintained through auto-regulation of *bmp* expression. For details, see text.](gr7){#f0035}
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